| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/28/2011 | US20110098215 Peptides and methods of use as therapeutics and screening agents |
| 04/28/2011 | US20110098214 Lps or lipid a binding agent and novel peptide |
| 04/28/2011 | US20110098213 Novel peptides for use in the treatment of obesity |
| 04/28/2011 | US20110098212 Cytokine |
| 04/28/2011 | US20110098211 Muteins with tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same |
| 04/28/2011 | US20110097794 Whitefly Ecdysone Receptor Nucleic Acids, Polypeptides, and Uses Thereof |
| 04/28/2011 | US20110097726 Regeneration and neogenesis of retinal photoreceptor cell using otx2 gene |
| 04/28/2011 | US20110097404 Tamper-resistant oral opioid agonist formulations |
| 04/28/2011 | US20110097391 Phospholipid Emulsion Containing Dihydroquercetin, and Method of Producing Thereof |
| 04/28/2011 | US20110097388 Methods of Expressing Proteins with Disulfide Bridges |
| 04/28/2011 | US20110097386 Stabilized glucagon solutions |
| 04/28/2011 | US20110097385 Delivery System for Drug and Cell Therapy |
| 04/28/2011 | US20110097383 Apparatus and methods for enzymatic escharotomy in burn induced compartment syndrome |
| 04/28/2011 | US20110097382 Methods and kits for reducing the likelihood of implantation failure and pregnancy-related disorders in recipients of artificial insemination |
| 04/28/2011 | US20110097379 Directed stem cell recruitment |
| 04/28/2011 | US20110097377 Methods and Devices for Correcting Spinal Deformity With Pharmaceutical-Eluting Pedicle Screws |
| 04/28/2011 | US20110097376 Radiopaque injectable nucleus hydrogel compositions |
| 04/28/2011 | US20110097374 Methods and Devices for Correcting Spinal Deformity With Pharmaceutical-Eluting Pedicle Screws |
| 04/28/2011 | US20110097367 Monolithic in-situ cross-linked alginate implants |
| 04/28/2011 | US20110097363 Therapeutically Effective Preparations of Insulin |
| 04/28/2011 | US20110097362 Transmucosal Administration of Aggregated Antigens |
| 04/28/2011 | US20110097352 Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
| 04/28/2011 | US20110097351 Compounds for treating beta-amyloidoses |
| 04/28/2011 | US20110097350 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| 04/28/2011 | US20110097347 Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad) |
| 04/28/2011 | US20110097337 Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells |
| 04/28/2011 | US20110097333 Therapeutic and diagnostic agents |
| 04/28/2011 | US20110097327 Product and method for treatment of conditions associated with receptor-desensitization |
| 04/28/2011 | US20110097325 Modulation of T cell Differentiation for the treatment of T helper cell mediated diseases |
| 04/28/2011 | US20110097324 Compositions and methods for modulating nicotinic/nmda receptor function |
| 04/28/2011 | US20110097318 Solid-State Protein Formulation |
| 04/28/2011 | US20110097317 Thioredoxin Interacting Protein (TXNIP) As Regulator Of Vascular Function |
| 04/28/2011 | US20110097316 Composition to be absorbed through mucous tissue |
| 04/28/2011 | US20110097315 Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one and salts thereof, useful in the treatment of cancer |
| 04/28/2011 | US20110097309 Pharmaceutical Agent for Promoting the Functional Regeneration of Damaged Tissue |
| 04/28/2011 | US20110097306 Oral formulations of cladribine |
| 04/28/2011 | US20110097305 Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors |
| 04/28/2011 | US20110097304 Compositions and methods for reducing the likelihood of spontaneous abortion in recipients of artifical insemination |
| 04/28/2011 | US20110097303 Methods and compositions for treating and preventing viral infections |
| 04/28/2011 | US20110097302 Il-1ra-polymer conjugates |
| 04/28/2011 | US20110097301 Angiogenesis promoted by caged growth factors |
| 04/28/2011 | US20110097300 Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis |
| 04/28/2011 | US20110097261 Amigo-2-inhibitors for treating, diagnosing or detecting cancer |
| 04/28/2011 | DE102009051575A1 Verwendung von biokompatiblen Zusammensetzungen und hieraus polymerisierten Materialien zur Inhibierung der Angiogenese Use of biocompatible compositions thereof and polymerised materials for the inhibition of angiogenesis |
| 04/28/2011 | CA2814958A1 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent |
| 04/28/2011 | CA2793835A1 Methods and compositions for cell-proliferation-related disorders |
| 04/28/2011 | CA2778695A1 Methods and compositions for enhancing polypeptide production |
| 04/28/2011 | CA2778533A1 Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof |
| 04/28/2011 | CA2778503A1 Macrocyclic inhibitors of serine protease enzymes |
| 04/28/2011 | CA2778392A1 Treatment of pre-term neonates |
| 04/28/2011 | CA2778390A1 Peptides used in the treatment and/or care of the skin, mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions |
| 04/28/2011 | CA2778359A1 Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof |
| 04/28/2011 | CA2778256A1 Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis |
| 04/28/2011 | CA2777883A1 Medical utility of glycan-binding proteins and glycans |
| 04/28/2011 | CA2777758A1 Peptidic glp-2 agonists |
| 04/27/2011 | EP2314708A1 Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| 04/27/2011 | EP2314699A1 Medical preparations for the treatment of alpha-galactosidase A deficiency |
| 04/27/2011 | EP2314697A1 Streptococcus pneumoniae proteins and nucleic acids |
| 04/27/2011 | EP2314696A1 Therapeutic uses of human Interleukin-B50 antagonist. |
| 04/27/2011 | EP2314695A2 Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily |
| 04/27/2011 | EP2314694A2 BAFF receptor (BCMA), an immunoregulatory agent |
| 04/27/2011 | EP2314690A1 RNA-interference by single-stranded RNA molecules |
| 04/27/2011 | EP2314687A1 Inducible small interfering RNA (siRNA) expression constructs for targeted gene silencing |
| 04/27/2011 | EP2314676A1 Compositions and methods for the treatment of immune related diseases |
| 04/27/2011 | EP2314675A2 Mutation in OAS1 genes |
| 04/27/2011 | EP2314627A2 Method for the treatment of multiple sclerosis |
| 04/27/2011 | EP2314616A1 Peptidic GLP-2 agonists |
| 04/27/2011 | EP2314615A2 Amylin family polypeptide-6 (afp-6) analogs and methods of making and using them |
| 04/27/2011 | EP2314612A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314611A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314610A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314601A1 Anti-inflammatory compounds and uses thereof |
| 04/27/2011 | EP2314600A1 Myocardial peptide, preparation method and uses thereof |
| 04/27/2011 | EP2314599A1 Glycopeptide antibiotic monomer derivatives |
| 04/27/2011 | EP2314598A1 Inhibitors of Hepatitis C virus NS3 serine protease |
| 04/27/2011 | EP2314595A2 Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
| 04/27/2011 | EP2314349A1 Anti-viral griffithsin compounds, compositions, and methods of use |
| 04/27/2011 | EP2314321A1 Formulations comprising antisense nucleotides to connexins |
| 04/27/2011 | EP2314312A2 Peptides and therapeutic application therefof |
| 04/27/2011 | EP2314311A2 Peptides and therapeutic application thereof |
| 04/27/2011 | EP2314308A1 Use of microproteins as tryptase inhibitors |
| 04/27/2011 | EP2314307A1 Enzyme-containing composition, process of producing said composition and its use |
| 04/27/2011 | EP2314306A1 Biological pacemaker |
| 04/27/2011 | EP2314305A2 Self-assembling peptide amphiphiles and related methods for growth factor delivery |
| 04/27/2011 | EP2314301A2 Sensitization of chemotherapeutic agent-resistant neoplastic cells with various viruses |
| 04/27/2011 | EP2314294A2 3,3'-diindolylmethane immune activating compositions |
| 04/27/2011 | EP2314293A1 Implantable device containing resorbable matrix material and rapamycin for preventing or treating vasuloproliferative diseases |
| 04/27/2011 | EP2314285A1 Lipophilic drug delivery vehicle and methods of us thereof |
| 04/27/2011 | EP2313783A2 Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them |
| 04/27/2011 | EP2313779A2 Use of defensin alpha 1 and/or defensin alpha 4, as a marker for predicting treatment response and/or a relapse in a patient suffering from chronic myeloid leukaemia |
| 04/27/2011 | EP2313432A1 Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders |
| 04/27/2011 | EP2313431A2 Long-acting interferons and derivatives thereof and methods thereof |
| 04/27/2011 | EP2313426A1 Novel protease inhibitors |
| 04/27/2011 | EP2313157A2 Cyclosporin derivatives for treating ocular and dermal diseases and conditions |
| 04/27/2011 | EP2313116A1 Improved bacterial polysaccharide-polypeptide conjugate compositions |
| 04/27/2011 | EP2313107A1 Catabolic agents |
| 04/27/2011 | EP2313106A2 Medical use of the radical scavenger and antioxidant alpha-1-microglobulin |
| 04/27/2011 | EP2313105A1 SOLUBLE HYBRID Fc RECEPTORS AND RELATED METHODS |
| 04/27/2011 | EP2313099A2 Use of rifalazil to treat colonic disorders |
| 04/27/2011 | EP2313097A2 Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |